LY03017
Phase 1Small molecule
Luye Pharma Group Ltd.LY03017 is one of 69 small molecule programs targeting Tics. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
108 competitors in Tics
#DrugCompanyPhaseTrials
1Sodium Valproate
AstraZenecaPhase 3
Priftin
SanofiPhase 2
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Duvyzat
ItalfarmacoPhase 2
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 2
Aciphex
Akero TherapeuticsPhase 1
Invokana
WWim Janssens
Phase 1
Tylenol
KKenvue Brands
Phase 1
Tarceva
OOSI Pharmaceuticals
Phase 1
Rifampicin
Boehringer IngelheimPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY03017. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company